T 03101Alternative Names: T 3101
Latest Information Update: 07 May 1998
At a glance
- Originator Antigenics; M. D. Anderson Cancer Center
- Class Antineoplastics
- Mechanism of Action RNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glioma
Most Recent Events
- 07 May 1998 Discontinued-Preclinical for Glioma in USA (Unknown route)
- 20 Feb 1995 Preclinical development for Glioma in USA (Unknown route)